2.80
price up icon2.56%   0.07
after-market 시간 외 거래: 2.80
loading
전일 마감가:
$2.73
열려 있는:
$2.74
하루 거래량:
1.46M
Relative Volume:
0.59
시가총액:
$251.78M
수익:
$32.31M
순이익/손실:
$-237.09M
주가수익비율:
-0.9722
EPS:
-2.88
순현금흐름:
$-219.11M
1주 성능:
-7.59%
1개월 성능:
-16.67%
6개월 성능:
+45.83%
1년 성능:
-26.12%
1일 변동 폭
Value
$2.7324
$2.921
1주일 범위
Value
$2.60
$3.08
52주 변동 폭
Value
$0.9101
$4.12

Editas Medicine Inc Stock (EDIT) Company Profile

Name
명칭
Editas Medicine Inc
Name
전화
617-401-9000
Name
주소
11 HURLEY ST., CAMBRIDGE, MA
Name
직원
226
Name
트위터
@editasmed
Name
다음 수익 날짜
2025-08-08
Name
최신 SEC 제출 서류
Name
EDIT's Discussions on Twitter

EDIT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
EDIT
Editas Medicine Inc
2.80 245.48M 32.31M -237.09M -219.11M -2.88
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-28 개시 H.C. Wainwright Buy
2024-12-16 다운그레이드 JP Morgan Neutral → Underweight
2024-12-13 다운그레이드 Chardan Capital Markets Buy → Neutral
2024-12-13 다운그레이드 Stifel Buy → Hold
2024-12-13 다운그레이드 Truist Buy → Hold
2024-12-11 다운그레이드 Wells Fargo Overweight → Equal Weight
2024-11-25 다운그레이드 BofA Securities Buy → Underperform
2024-11-06 업그레이드 Evercore ISI In-line → Outperform
2024-11-04 다운그레이드 Raymond James Outperform → Mkt Perform
2024-08-08 업그레이드 BofA Securities Neutral → Buy
2024-05-09 업그레이드 Morgan Stanley Underweight → Equal-Weight
2023-10-24 업그레이드 Citigroup Neutral → Buy
2023-10-18 업그레이드 JP Morgan Underweight → Neutral
2023-10-17 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2023-09-29 업그레이드 Stifel Hold → Buy
2023-06-12 업그레이드 Raymond James Mkt Perform → Outperform
2023-02-01 개시 Cantor Fitzgerald Overweight
2022-12-13 개시 Citigroup Neutral
2022-12-06 재개 Credit Suisse Neutral
2022-11-18 다운그레이드 Credit Suisse Outperform → Neutral
2022-11-18 다운그레이드 Oppenheimer Outperform → Perform
2022-09-29 개시 BofA Securities Neutral
2021-10-19 개시 SVB Leerink Mkt Perform
2021-09-24 개시 Stifel Hold
2021-09-10 업그레이드 Oppenheimer Perform → Outperform
2021-08-09 업그레이드 Truist Hold → Buy
2021-08-05 업그레이드 Evercore ISI Underperform → Outperform
2021-06-04 재개 Robert W. Baird Outperform
2021-05-04 개시 RBC Capital Mkts Sector Perform
2021-04-16 개시 Goldman Sell
2021-03-22 개시 Credit Suisse Outperform
2021-03-01 다운그레이드 Barclays Overweight → Equal Weight
2021-02-26 다운그레이드 Truist Buy → Hold
2021-01-19 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2021-01-07 다운그레이드 Raymond James Outperform → Mkt Perform
2020-12-10 업그레이드 Wells Fargo Equal Weight → Overweight
2020-11-03 개시 Robert W. Baird Underperform
2020-06-18 재개 SunTrust Buy
2020-02-21 개시 Wells Fargo Equal Weight
2019-04-12 개시 Evercore ISI Outperform
2018-10-10 개시 Guggenheim Neutral
2018-09-21 개시 Raymond James Outperform
2018-05-15 재확인 Chardan Capital Markets Buy
2018-02-13 개시 CLSA Underperform
2018-01-23 업그레이드 SunTrust Hold → Buy
2017-07-14 개시 SunTrust Hold
2017-03-28 개시 Chardan Capital Markets Buy
2016-08-10 업그레이드 Jefferies Hold → Buy
2016-06-02 개시 Jefferies Hold
2016-02-29 개시 JMP Securities Mkt Outperform
2016-02-29 개시 JP Morgan Neutral
2016-02-29 개시 Morgan Stanley Equal-Weight
모두보기

Editas Medicine Inc 주식(EDIT)의 최신 뉴스

pulisher
Aug 20, 2025

Editas Medicine (NASDAQ:EDIT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat

Aug 20, 2025
pulisher
Aug 20, 2025

Editas Medicine Inc. Moves Into Overbought Range Analysts CautiousPrice Action & Stepwise Swing Trade Plans - beatles.ru

Aug 20, 2025
pulisher
Aug 19, 2025

Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results - MarketBeat

Aug 19, 2025
pulisher
Aug 18, 2025

Editas Medicine (NASDAQ:EDIT) Price Target Raised to $6.00 at Robert W. Baird - MarketBeat

Aug 18, 2025
pulisher
Aug 18, 2025

Short interest data insights for Editas Medicine Inc.2025 Market Trends & Low Risk High Win Rate Stock Picks - Newser

Aug 18, 2025
pulisher
Aug 17, 2025

Intraday pattern recognizer results for Editas Medicine Inc.July 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

How to recover losses in Editas Medicine Inc. stockPortfolio Growth Summary & Low Drawdown Trading Techniques - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Ranking Editas Medicine Inc. among high performing stocks via toolsJuly 2025 Technicals & Fast Moving Trade Plans - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

How to build a custom watchlist for Editas Medicine Inc.Weekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Trend analysis for Editas Medicine Inc. this weekWeekly Trend Recap & Comprehensive Market Scan Insights - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

What makes Editas Medicine Inc. stock price move sharplyTrend Reversal & High Accuracy Buy Signal Tips - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Is Editas Medicine Inc. showing signs of accumulationMarket Growth Review & High Accuracy Buy Signal Tips - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

HC Wainwright Boosts Editas Medicine Price Target to $5.00, Analysts Predict 22.47% Upside - AInvest

Aug 16, 2025
pulisher
Aug 16, 2025

Editas Medicine's Q2 Earnings Boost Stock Price 34% Amid Plans to Nominate First In Vivo Development Candidate in September - AInvest

Aug 16, 2025
pulisher
Aug 16, 2025

Editas Medicine (NASDAQ:EDIT) Downgraded to Sell Rating by Wall Street Zen - Defense World

Aug 16, 2025
pulisher
Aug 15, 2025

Why Editas Medicine Inc. stock attracts strong analyst attentionJuly 2025 Pullbacks & Free Verified High Yield Trade Plans - sundaytimes.kr

Aug 15, 2025
pulisher
Aug 15, 2025

Editas Medicine: Strategic Position Balances Cautious Development and Financial Stability - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

What drives Editas Medicine Inc.’s stock priceProduct Launch & Daily Technical Stock Forecast Reports - thegnnews.com

Aug 15, 2025
pulisher
Aug 15, 2025

Why Editas Medicine Stock Was Skyrocketing This Week - AOL.com

Aug 15, 2025
pulisher
Aug 15, 2025

H.C. Wainwright raises Editas Medicine stock price target to $5 on pipeline progress - Investing.com Canada

Aug 15, 2025
pulisher
Aug 15, 2025

Editas Medicine: HC Wainwright Raises PT to $5, Maintains Buy Rating - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Robert W. Baird Forecasts Strong Price Appreciation for Editas Medicine (NASDAQ:EDIT) Stock - Defense World

Aug 15, 2025
pulisher
Aug 14, 2025

How Interest Rate Changes Impact Editas Medicine Inc. Stock PerformanceMarket Movement Recap & Daily Profit Focused Stock Screening - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Editas Medicine Inc. Rebound Backed by Sentiment Shift2025 Price Action Summary & Consistent Income Trade Recommendations - sundaytimes.kr

Aug 14, 2025
pulisher
Aug 14, 2025

Applications Of Genetic Engineering Market is Booming Worldwide | Editas Medicine , Intellia Therapeutics - newstrail.com

Aug 14, 2025
pulisher
Aug 14, 2025

Editas Medicine Inc. Pullback Analyzed — Is It Time to Exit2025 Sector Review & Weekly Chart Analysis and Trade Guides - sundaytimes.kr

Aug 14, 2025
pulisher
Aug 13, 2025

Editas Medicine Reports Q2 2025 Progress and Financials - TipRanks

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine’s SWOT analysis: gene editing stock faces challenges, opportunities - Investing.com

Aug 13, 2025
pulisher
Aug 13, 2025

A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $6 - 富途牛牛

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine shares surge 28.87% intraday after strong Q2 earnings and positive analyst ratings. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine Surges 34% on Q2 Momentum and Strategic Milestones – What’s Fueling the Biotech Rally? - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Can Editas Medicine Inc. Regain Momentum After BreakdownQuarterly Profit Review & Precise Buy Zone Identification - 선데이타임즈

Aug 13, 2025
pulisher
Aug 13, 2025

Baird raises Editas Medicine stock price target to $6 on pipeline progress - Investing.com Nigeria

Aug 13, 2025
pulisher
Aug 13, 2025

Editas: Q2 Earnings Snapshot - Greenwich Time

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates - MSN

Aug 13, 2025
pulisher
Aug 13, 2025

What high frequency data says about Editas Medicine Inc.2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine 2025 Q2 Earnings Narrows Losses Amid Revenue Surge - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine Announces Second Quarter 2025 Results and Business Updates - GlobeNewswire

Aug 13, 2025
pulisher
Aug 12, 2025

Editas Medicine's Q2 Performance: Assessing Progress Amid Financial Challenges - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine Misses Expectations But Stays Focused On The Future - Finimize

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine earnings missed by $0.23, revenue topped estimates - Investing.com Canada

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine Inc Q2 2025 Earnings: Revenue Soars to $3.6M, Beating Estimates; EPS Misses at -$0.63 - GuruFocus

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine posts Q2 net loss of $53.2 mln - MarketScreener

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine Q2 2025: On track to file IND by mid-2026, proof-of-concept by year-end. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine Reports Q2 2025 Results, Advances Gene Editing Programs - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine narrows losses as Bristol Myers Squibb partnership hits key milestone - Stock Titan

Aug 12, 2025

Editas Medicine Inc (EDIT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Editas Medicine Inc 주식 (EDIT) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Jul 31 '25
Sale
2.49
5,121
12,757
64,398
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
자본화:     |  볼륨(24시간):